In the context of sepsis-induced skeletal muscle atrophy, the use of NLRP3 inhibitors has shown promising effects in alleviating the condition by inhibiting catabolic processes and cachexia-associated inflammation [20]. This evidence concerns the gene NLRP3 and Sepsis.